ATE326985T1 - Lyophilisierte pharmazeutische zusammensetzung von propofol - Google Patents

Lyophilisierte pharmazeutische zusammensetzung von propofol

Info

Publication number
ATE326985T1
ATE326985T1 AT03702813T AT03702813T ATE326985T1 AT E326985 T1 ATE326985 T1 AT E326985T1 AT 03702813 T AT03702813 T AT 03702813T AT 03702813 T AT03702813 T AT 03702813T AT E326985 T1 ATE326985 T1 AT E326985T1
Authority
AT
Austria
Prior art keywords
propofol
pharmaceutical composition
lyophilized pharmaceutical
relates
composition
Prior art date
Application number
AT03702813T
Other languages
English (en)
Inventor
Lawrence John Penkler
Barry Paul Daisley
Original Assignee
Shimoda Biotech Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shimoda Biotech Pty Ltd filed Critical Shimoda Biotech Pty Ltd
Application granted granted Critical
Publication of ATE326985T1 publication Critical patent/ATE326985T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03702813T 2002-02-01 2003-01-29 Lyophilisierte pharmazeutische zusammensetzung von propofol ATE326985T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA200200929 2002-02-01
US40163302P 2002-08-06 2002-08-06

Publications (1)

Publication Number Publication Date
ATE326985T1 true ATE326985T1 (de) 2006-06-15

Family

ID=27669352

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03702813T ATE326985T1 (de) 2002-02-01 2003-01-29 Lyophilisierte pharmazeutische zusammensetzung von propofol

Country Status (12)

Country Link
US (1) US20050239746A1 (de)
EP (1) EP1469886B8 (de)
JP (1) JP2005522422A (de)
CN (1) CN1625414A (de)
AT (1) ATE326985T1 (de)
AU (1) AU2003205930B2 (de)
BR (1) BR0307518A (de)
CA (1) CA2474710A1 (de)
DE (1) DE60305438T2 (de)
MX (1) MXPA04007328A (de)
NZ (1) NZ534598A (de)
WO (1) WO2003063824A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE364402T1 (de) * 2004-03-10 2007-07-15 Shimoda Biotech Pty Ltd Stabile injizierbare diclofenac- zubereitungen
US20060198891A1 (en) 2004-11-29 2006-09-07 Francois Ravenelle Solid formulations of liquid biologically active agents
WO2006112276A1 (ja) 2005-04-13 2006-10-26 Otsuka Pharmaceutical Factory, Inc. プロポフォール含有脂肪乳剤
US20090203794A1 (en) * 2005-08-12 2009-08-13 Gautam Vinod Daftary Aqueous Anaesthetic Composition Comprising Propofol
US8580954B2 (en) 2006-03-28 2013-11-12 Hospira, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
EP2106786A1 (de) * 2008-04-04 2009-10-07 Roewer, Norbert, Univ.-Prof. Dr. med. Pharmazeutische Zubereitung mit permethyliertem Cyclodextrin
DK2484350T3 (en) * 2011-02-04 2016-08-01 Norbert Univ -Prof Dr Med Roewer A pharmaceutical composition containing a complex of a cyclodextrin with a propofolsalt
HRP20200567T1 (hr) * 2011-11-29 2020-06-26 Jurox Pty Ltd Stabilni injektabilni farmaceutski pripravci koji sadrže 2-hidroksipropil-beta-ciklodekstrin i alfaksalon
CN103172658B (zh) * 2011-12-26 2016-01-20 宜昌人福药业有限责任公司 一种适合药用的前体药物晶型、制备方法及药用组合物
KR102147084B1 (ko) 2012-11-15 2020-08-24 자피오텍 게엠베하 소염성 활성 물질 또는 면역 억제성 활성물질로서 델피니딘 복합제
CN104918622A (zh) 2012-12-11 2015-09-16 赛博尔泰克股份公司 用于对抗黑色素瘤细胞的飞燕草素
EP2913050A1 (de) * 2014-02-28 2015-09-02 SapioTec GmbH Verfahren zur Herstellung eines Flurankomplexes
CN104523591B (zh) * 2014-12-19 2019-01-18 西安力邦肇新生物科技有限公司 无致敏性、无痛丙泊酚脂肪微乳冻干制剂配方和制备方法
CN111529695A (zh) * 2020-04-30 2020-08-14 首都医科大学附属北京康复医院(北京工人疗养院) 一种环糊精可溶性ace2及其制备方法和应用
KR20220057901A (ko) * 2020-10-30 2022-05-09 현대자동차주식회사 차아염소산수를 이용한 차량용 살균장치 및 그 제어방법
FR3117337B1 (fr) 2020-12-10 2023-04-28 Centre Hospitalier Univ De Lille Composition pharmaceutique contenant du propofol, une cyclodextrine ou un dérivé de cyclodextrine et un sel pharmaceuticalement acceptable
KR20240148426A (ko) * 2022-02-18 2024-10-11 베렌 테라퓨틱스 피.비.씨. 2-히드록시프로필-베타-사이클로덱스트린으로 고-트리글리세리드혈증을 치료

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA828580B (en) * 1981-12-23 1983-10-26 Schering Corp Interferon formulations
ZA962214B (en) * 1995-04-10 1996-10-07 Farmarc Nederland Bv Pharmaceutical composition
AU5774796A (en) * 1995-06-13 1997-01-09 Dyer, Alison Margaret Pharmaceutical compositions containing lornoxicam and cyclod extrin
PL328406A1 (en) * 1996-02-19 1999-01-18 Nycomed Imaging As Improved contrast media
US6407278B2 (en) * 1998-11-16 2002-06-18 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and methods for the preparation and use of the same
US6440414B1 (en) * 1999-10-01 2002-08-27 Amgen Inc. Pharmaceutical compositions of fibrinolytic agent
JP4854899B2 (ja) * 1999-10-29 2012-01-18 メルク・シャープ・エンド・ドーム・コーポレイション カルバペネム系抗生物質組成物の処方方法
IN187686B (de) * 2000-06-21 2002-06-08 Bharat Serums & Vaccines Ltd
WO2002074200A1 (en) * 2001-03-20 2002-09-26 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin

Also Published As

Publication number Publication date
EP1469886A2 (de) 2004-10-27
MXPA04007328A (es) 2005-07-05
JP2005522422A (ja) 2005-07-28
EP1469886B1 (de) 2006-05-24
NZ534598A (en) 2004-11-26
DE60305438T2 (de) 2006-12-21
WO2003063824A3 (en) 2004-06-17
WO2003063824A2 (en) 2003-08-07
AU2003205930B2 (en) 2007-08-16
CN1625414A (zh) 2005-06-08
US20050239746A1 (en) 2005-10-27
CA2474710A1 (en) 2003-08-07
BR0307518A (pt) 2004-12-28
DE60305438D1 (de) 2006-06-29
EP1469886B8 (de) 2008-01-09

Similar Documents

Publication Publication Date Title
DE60305438D1 (de) Lyophilisierte pharmazeutische zusammensetzung von propofol
HU230005B1 (en) Topical composition containing at least one vitamin d or one vitamin d analogue and at least one corticosteroid
DK1187928T3 (da) Viruslignende partikler, fremstilling og anvendelse ved screening samt ved funktionel genomics
BR0113663A (pt) Composições de pelìcula de pectina
BR0315275A (pt) Anticorpos que se ligam a receptor de eritropoietina
FR2841900B1 (fr) Nouveaux derives de 1,3-diphenylprop-2-en-1-one substitues, preparation et utilisations
ATE250431T1 (de) Verbesserte zusammensetzungen mit unkomplexiertem cyclodextrin zur geruchskontrolle
SG170087A1 (en) Pharmaceutical compositions
HRP20080564T3 (hr) Dihidrotetrabenazini i farmaceutski pripravci koji ih sadrže
NO20035301D0 (no) Små molekyl¶re antagonister av proteiner i BCL-2-familien
ATE350377T1 (de) Substituierte 3-pyrrolidin-indol-derivate
CY1118180T1 (el) Μεθοδος για παρασκευη στερεας φαρμακευτικης συνθεσης
EP1505990A4 (de) Verfahren zur behandlung von hepatitis
BRPI0508700A (pt) uso de sns-595, composição farmacêutica, e, pó liofilizado
TW200501965A (en) Highly pure fondaparinux sodium composition,process for preparing said composition and pharmaceutical compositions containing it as active principle
BR0308486A (pt) Composição tópica compreendendo um ciclofrutano, um veìculo e uma droga
DE60113445D1 (de) Substanzen mit verzweigten linkermolekülen
UY27929A1 (es) Composiciones farmaceuticas de farmacos semiordenados y polimeros
DE602004017326D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
DE69924304D1 (de) N-palmitoylethanolamid-enthaltende pharmazeutische zusammensetzungen und deren verwendung in der veterinärmedizin
DE60121804D1 (de) Pharmazeutische zusammensetzung eines biguanin (metformin) und arginin
EA200601288A1 (ru) Производные 1,3-дифенилпроп-2-ен-1-она, способ их получения и применение
EA200100674A1 (ru) Клатраты дегидроэпиандростерона и соответствующие фармацевтические композиции
EA200501301A1 (ru) Ментоловые растворы лекарственных препаратов
SE0300457D0 (sv) Novel compounds

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties